Patient tagging device for reducing medical errors gets US nod
This article was originally published in Clinica
The FDA has cleared for sale in the US a noninvasive tagging system aimed at safeguarding against surgical mishaps. The skin-mounted adhesive, called SurgiChip, is expected to remove the risk of patients being given the wrong surgical procedure or treated at the wrong site of injury. The product's Palm Beach Gardens, Florida based developer, also known as SurgiChip, says the product is the first external surgical marker to implement radiofrequency identification (RFID) technology.
You may also be interested in...
GSK commits to investing behind OTC and oral health brands in India after offloading nutrition assets to Unilever.
The Belgian biotech has managed to attract considerable sums from venture capitalists over the past couple of years amid hopes that its two next-generation immunotherapies will be best-in-class agents.
Cipla is celebrating an “important milestone” for the company after the successful completion of a Phase III clinical trial comparing its proposed Advair generic with GSK’s brand in the US. Management has cautioned that approval will be a way off yet, however.